Skip to main content
Premium Trial:

Request an Annual Quote

DeCode s Q1 Revenues Increase 9 Percent

NEW YORK, May 16 – DeCode Genetics’ revenues rose nine percent to $5.0 million in the first quarter as milestone revenues increased.

Expenditures for the quarter more than doubled to $20.2 million, compared with $9.2 million in the year ago period as the company expanded its research activities and incurred higher general and administrative expenses.

During the first quarter, DeCode delivered schizophrenia and peripheral arterial occlusive targets to Roche as part of its alliance to develop diagnostics. The company said it expects to post near- and medium-term revenue growth stemming from milestone payments related to the five-year alliance, details of which are scheduled to be announced during the next few weeks.

DeCode of Reykjavik, Iceland, said it also entered new partnerships in gene discovery, pharmacogenomics, database services, and bioinformatics.

The company had net losses of  $16.1 million, or 37 cents a share, compared with net losses of $6.9 million, or 23 cents a share, a year ago.

As of the end of March DeCode had about $172 million in cash and cash equivalents.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more